The reinforcing effects of nicotine in humans and nonhuman primates: A review of intravenous self-administration evidence and future directions for research

Nicotine and Tobacco Research

Volumn 17, Issue 11, 2015, Pages 1297-1310

  Goodwin, Amy K ^a   Hiranita, Takato ^a   Paule, Merle G ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; COCAINE; LEFETAMINE; MECAMYLAMINE; MORPHINE; NICOTINE; SODIUM CHLORIDE; GANGLION STIMULATING AGENT;

ANIMAL BEHAVIOR; DRUG SELF ADMINISTRATION; FOOD DEPRIVATION; HUMAN; INFUSION RATE; INTRAVENOUS CATHETER; NONHUMAN; PAPIO ANUBIS; PAPIO HAMADRYAS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REINFORCEMENT; REVIEW; SAIMIRI SCIUREUS; SATIETY; SMOKING; TOBACCO DEPENDENCE; ANIMAL; BEHAVIOR; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; PRIMATE;

ANIMALS; BEHAVIOR; GANGLIONIC STIMULANTS; HUMANS; INJECTIONS, INTRAVENOUS; NICOTINE; PRIMATES; REINFORCEMENT (PSYCHOLOGY); SMOKING;

EID: 84945488351     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv002     Document Type: Review

References (117)

1. Centers for Disease Control and Prevention. Smoking & Tobacco Use, Data and Statistics, Fact Sheets. 2012. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/index.htm. Accessed December 22, 2014.
2. Centers for Disease Control and Prevention. Preventing Tobacco Use Among Young and Young Adults: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smonking and Health; 2012. http://www.surgeongeneral.gov/library/reports/preventing-youth-tobaccouse/. Accessed December 22, 2014.
3. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368:341-350.
4. Centers for Disease Control and Prevention. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. http://www.surgeongeneral.gov/library/reports/50-years-of-progress/. Accessed December 22, 2014.
5. Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31; 2009. http://www.gpo.gov/fdsys/pkg/PLAW-111publ31/pdf/PLAW-111publ31.pdf. Accessed December 22, 2014.
6. Ashley DL, Backinger CL. The Food and Drug Administration's regulation of tobacco: the Center for Tobacco Products' Office of Science. Am J Prev Med. 2012;43(suppl 3):S255-263.
7. Centers for Disease Control and Prevention. The Health Consequences of Smoking: Nicotine Addiction. Rockville, MD: US Department of Health and Human Services Centers for Disease Control, Office on Smoking and Health; 1988. http://profiles.nlm.nih.gov/ps/access/NNBBZD.pdf. Accessed December 22, 2014.
8. Henningfield JE, Heishman SJ. The addictive role of nicotine in tobacco use. Psychopharmacology (Berl). 1995;117:11-13.
9. Hurt RD, Robertson CR. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA. 1998;280:1173-1181.
10. Stolerman IP, Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol Sci. 1991;12:467-473.
11. Henningfield JE, Goldberg SR. Progress in understanding the relationship between the pharmacological effects of nicotine and human tobacco dependence. Pharmacol Biochem Behav. 1988;30:217-220.
12. Centers for Disease Control and Prevention. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: Public Health Service, U.S. Department of Health, Education, and Welfare; 1964. http://profiles.nlm.nih.gov/NN/B/B/M/Q/. Accessed December 22, 2014.
13. Centers for Disease Control and Prevention. The Health Consequences of Smoking. Washington, DC: Center for Disease Control, Public Health Service, U.S. Department of Health, Education, and Welfare; 1974. http://profiles.nlm.nih.gov/NN/B/B/Q/N/. Accessed December 22, 2014.
14. Benowitz NL, Jacob P III. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther. 1984;35:499-504.
15. Benowitz NL, Jacob P III. Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J Pharmacol Exp Ther. 1990;254:1000-1005. http://jpet.aspetjournals.org/content/254/3/1000.long. Accessed December 22, 2014.
16. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79-115.
17. Kozlowski LT, Mehta NY, Sweeney CT, et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. Tob Control. 1998;7:369-375.
18. Matta SG, Balfour DJ, Benowitz NL, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl). 2007;190:269-319.
19. Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 2003;70:S55-72.
20. Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev. 2009;18:3241-3262.
21. Haney M, Spealman R. Controversies in translational research: drug selfadministration. Psychopharmacology (Berl). 2008;199:403-419.
22. Horton DB, Potter DM, Mead AN. A translational pharmacology approach to understanding the predictive value of abuse potential assessments. Behav Pharmacol. 2013;24:410-436.
23. Le Foll B, Goldberg SR. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol. 2009;192:335-367. doi: 10.1007/978-3-540-69248-5_12.
24. Dar R, Frenk H. Nicotine self-administration in animals: a reevaluation. Addict Res Theory. 2002;10:545-579.
25. Caille S, Clemens K, Stinus L, Cador M. Modeling nicotine addiction in rats. Methods Mol Biol. 2012;829:243-256.
26. LeSage MG, Perry JL, Kotz CM, Shelley D, Corrigall WA. Nicotine selfadministration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology (Berl). 2010;209:203-212.
27. Levin ED, Slade S, Wells C, et al. Threshold of adulthood for the onset of nicotine self-administration in male and female rats. Behav Brain Res. 2011;225:473-481.
28. Liu X. Positive allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. Psychopharmacology (Berl). 2013;230:203-213.
29. Liu X, Caggiula AR, Yee SK, et al. Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats. Neuropsychopharmacology. 2007;32:710-718.
30. O'Dell LE, Khroyan TV. Rodent models of nicotine reward: what do they tell us about tobacco abuse in humans? Pharmacol Biochem Behav. 2009;91:481-488.
31. Deneau GA, Inoki R. Nicotine self-administration in monkeys. Ann N Y Acad Sci. 1967;142:277-279.
32. Yanagita T. Brief review on the use of self-administration techniques for predicting drug dependence potential. In: Thompson T, Unna KR, eds. Predicting Dependence Liability of Stimulant and Depressant Drugs. Baltimore, MD: University Park Press; 1977:231-242.
33. Yanagita T, Ando K, Kato S, Takada K. Psychopharmacological studies on nicotine and tobacco smoking in rhesus monkeys. Psychopharmacol Bull. 1983;19:409-412.
34. Meisch RA, Lemaire GA. Drug self-administration. In: Van Haaren F, ed. Methods in Behavioral Pharmacology. Vol 10. New York, NY: Elsevier; 1993:257-293.
35. Griffiths RR, Brady JV, Bradford LD. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. In: Thompson T, Dews PB, eds. Advances in behavioral pharmacology. Vol 2. New York, NY: Academic Press; 1979:163-208.
36. Ator NA, Griffiths RR. Nicotine self-administration in baboons. Pharmacol Biochem Behav. 1983;19:993-1003.
37. Goldberg SR, Spealman RD, Goldberg DM. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science. 1981;214:573-575. http://www.sciencemag.org/content/214/4520/573. long. Accessed December 22, 2014.
38. Goldberg SR, Spealman RD. Maintenance and suppression of behavior by intravenous nicotine injections in squirrel monkeys. Fed Proc. 1982;41:216-220.
39. Spealman RD, Goldberg SR. Maintenance of schedule-controlled behavior by intravenous injections of nicotine in squirrel monkeys. J Pharmacol Exp Ther. 1982;223:402-408. http://jpet.aspetjournals.org/content/223/2/402.full.pdf+html. Accessed December 22, 2014.
40. Dougherty J, Miller D, Todd G, Kostenbauder HB. Reinforcing and other behavioral effects of nicotine. Neurosci Biobehav Rev. 1981;5:487-495.
41. Slifer BL. Schedule-induction of nicotine self-administration. Pharmacol Biochem Behav. 1983;19:1005-1009.
42. Slifer BL, Balster RL. Intravenous self-administration of nicotine: with and without schedule-induction. Pharmacol Biochem Behav. 1985;22:61-69.
43. de la Garza R, Johanson CE. The effects of food deprivation on the self-administration of psychoactive drugs. Drug Alcohol Depend. 1987;19:17-27.
44. Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav. 1973;20:119-129.
45. Beardsley PM, Balster RL. The effects of delay of reinforcement and dose on the self-administration of cocaine and procaine in rhesus monkeys. Drug Alcohol Depend. 1993;34:37-43.
46. Galuska CM, Woods JH. Acquisition of cocaine self-administration with unsignaled delayed reinforcement in rhesus monkeys. J Exp Anal Behav. 2005;84:269-280.
47. Wakasa Y, Takada K, Yanagita T. Reinforcing effect as a function of infusion speed in intravenous self-administration of nicotine in rhesus monkeys. Nihon Shinkei Seishin Yakurigaku Zasshi. 1995;15:53-59.
48. Gould RW, Czoty PW, Nader SH, Nader MA. Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther. 2011;339:678-686.
49. Freeman KB, Woolverton WL. Self-administration of cocaine and nicotine mixtures by rhesus monkeys. Psychopharmacology (Berl). 2009;207:99-106.
50. Le Foll B, Wertheim C, Goldberg SR. High reinforcing efficacy of nicotine in non-human primates. PLoS One. 2007;2:e230.
51. Caggiula AR, Donny EC, White AR, et al. Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav. 2001;70:515-530.
52. Caggiula AR, Donny EC, Chaudhri N, Perkins KA, Evans-Martin FF, Sved AF. Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav. 2002;77:683-687.
53. Donny EC, Chaudhri N, Caggiula AR, et al. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl). 2003;169:68-76.
54. Justinová Z, Yasar S, Redhi GH, Goldberg SR. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. J Neurosci. 2011;31:7043-7048.
55. Mascia P, Pistis M, Justinova Z, et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry. 2011;69:633-641.
56. Panlilio LV, Justinova Z, Mascia P, et al. Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Neuropsychopharmacology. 2012;37:1838-1847.
57. Mello NK, Newman JL. Discriminative and reinforcing stimulus effects of nicotine, cocaine, and cocaine + nicotine combinations in rhesus monkeys. Exp Clin Psychopharmacol. 2011;19:203-214.
58. Mello NK, Fivel PA, Kohut SJ. Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration. Neuropsychopharmacology. 2013;38:1264-1275.
59. Mello NK, Fivel PA, Kohut SJ, Carroll FI. Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine selfadministration. Neuropsychopharmacology. 2014;39:1222-1231.
60. Sannerud CA, Prada J, Goldberg DM, Goldberg SR. The effects of sertraline on nicotine self-administration and food-maintained responding in squirrel monkeys. Eur J Pharmacol. 1994;271:461-469.
61. Mello NK, Fivel PA, Kohut SJ, Caine SB. Anatabine significantly decreases nicotine self-administration. Exp Clin Psychopharmacol. 2014;22:1-8.
62. Henningfield JE, Miyasato K, Jasinski DR. Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav. 1983;19:887-890.
63. Henningfield JE, Goldberg SR. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav. 1983;19:1021-1026.
64. Henningfield JE, Goldberg SR. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav. 1983;19:989-992.
65. Rose JE, Behm FM, Westman EC, et al. PET studies of the influences of nicotine on neural systems in cigarette smokers. Am J Psychiatry. 2003;160:323-333.
66. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl). 2004;175:134-142.
67. Sofuoglu M, Yoo S, Hill KP, Mooney M. Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology. 2008;33:715-720.
68. Rose JE, Salley A, Behm FM, Bates JE, Westman EC. Reinforcing effects of nicotine and non-nicotine components of cigarette smoke. Psychopharmacology (Berl). 2010;210:1-12.
69. Benowitz NL, Henningfield JE. Reducing the nicotine content to make cigarettes less addictive. Tob Control. 2013;22(suppl 1):i14-17.
70. Donny EC, Taylor TG, LeSage MG, et al. Impact of tobacco regulation on animal research: new perspectives and opportunities. Nicotine Tob Res. 2012;14:1319-1338.
71. Gray N, Henningfield JE, Benowitz NL, et al. Toward a comprehensive long term nicotine policy. Tob Control. 2005;14:161-165.
72. Hatsukami DK, Perkins KA, Lesage MG, et al. Nicotine reduction revisited: science and future directions. Tob Control. 2010;19:e1-10.
73. Hatsukami DK, Benowitz NL, Donny E, Henningfield J, Zeller M. Nicotine reduction: strategic research plan. Nicotine Tob Res. 2013;15:1003-1013.
74. Sofuoglu M, LeSage MG. The reinforcement threshold for nicotine as a target for tobacco control. Drug Alcohol Depend. 2012;125:1-7.
75. Smith TT, Levin ME, Schassburger RL, Buffalari DM, Sved AF, Donny EC. Gradual and immediate nicotine reduction result in similar low-dose nicotine self-administration. Nicotine Tob Res. 2013;15:1918-1925.
76. Donny EC, Houtsmuller E, Stitzer ML. Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction. 2007;102:324-334.
77. Pierce JP, White VM, Emery SL. What public health strategies are needed to reduce smoking initiation? Tob Control. 2012;21:258-264.
78. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and and Health: Summary of National Findings. In: HHS, ed. Vol NSDUH Series H-41. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2010. http://atforum.com/documents/NSDUH2010.pdf. Accessed December 22, 2014.
79. Levin ED, Lawrence SS, Petro A, et al. Adolescent vs. adult-onset nicotine self-administration in male rats: duration of effect and differential nicotinic receptor correlates. Neurotoxicol Teratol. 2007;29:458-465.
80. Kendler KS, Myers J, Damaj MI, Chen X. Early smoking onset and risk for subsequent nicotine dependence: a monozygotic co-twin control study. Am J Psychiatry. 2013;170:408-413.
81. Moolchan ET, Ernst M, Henningfield JE. A review of tobacco smoking in adolescents: treatment implications. J Am Acad Child Adolesc Psychiatry. 2000;39:682-693.
82. Riggs NR, Chou CP, Li C, Pentz MA. Adolescent to emerging adulthood smoking trajectories: when do smoking trajectories diverge, and do they predict early adulthood nicotine dependence? Nicotine Tob Res. 2007;9:1147-1154.
83. Goodwin AK, Lantz-McPeak SM, Robinson BL, Law CD, Ali SF, Ferguson SA. Effects of adolescent treatment with nicotine, harmane, or norharmane in male Sprague-Dawley rats. Neurotoxicol Teratol. 2015;47:25-35.
84. Spear LP. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev. 2000;24:417-463.
85. Levin ED, Rezvani AH, Montoya D, Rose JE, Swartzwelder HS. Adolescent-onset nicotine self-administration modeled in female rats. Psychopharmacology (Berl). 2003;169:141-149.
86. Natividad LA, Torres OV, Friedman TC, O'Dell LE. Adolescence is a period of development characterized by short-and long-term vulnerability to the rewarding effects of nicotine and reduced sensitivity to the anorectic effects of this drug. Behav Brain Res. 2013;257:275-285.
87. Adriani W, Spijker S, Deroche-Gamonet V, et al. Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats. J Neurosci. 2003;23:4712-4716. http://www.jneurosci.org/content/23/11/4712.long. Accessed December 22, 2014.
88. Huang HY, Hsieh SH. Analyses of tobacco alkaloids by cation-selective exhaustive injection sweeping microemulsion electrokinetic chromatography. J Chromatogr A. 2007;1164:313-319.
89. Houlgate PR, Dhingra KS, Nash SJ, Evans WH. Determination of formaldehyde and acetaldehyde in mainstream cigarette smoke by highperformance liquid chromatography. Analyst. 1989;114:355-360.
90. Xie J, Yin J, Sun S, Xie F, Zhang X, Guo Y. Extraction and derivatization in single drop coupled to MALDI-FTICR-MS for selective determination of small molecule aldehydes in single puff smoke. Anal Chim Acta. 2009;638:198-201.
91. Castagnoli K, Steyn SJ, Magnin G, et al. Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase. Neurotox Res. 2002;4:151-160.
92. Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun. 2005;326:378-386.
93. Poindexter EH Jr, Carpenter RO. The isolation of harmane and norharmance from tobacco and cigarette smoke. Phytochemistry. 1962;1:215-221.
94. U.S. Food and Drug Administration. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List. In: HHS, ed. FDA-2012-N-01432012. U.S. Food and Drug Administration; 2012. http://www.fda.gov/tobaccoproducts/guidancecomplianceregulatoryinformation/ucm297786.Htm. Accessed December 22, 2014.
95. Myers WD, Ng KT, Singer G. Intravenous self-administration of acetaldehyde in the rat as a function of schedule, food deprivation and photoperiod. Pharmacol Biochem Behav. 1982;17:807-811.
96. Myers WD, Ng KT, Singer G. Effects of naloxone and buprenorphine on intravenous acetaldehyde self-injection in rats. Physiol Behav. 1984;33:449-455.
97. Myers WD, Ng KT, Marzuki S, Myers RD, Singer G. Alteration of alcohol drinking in the rat by peripherally self-administered acetaldehyde. Alcohol. 1984;1:229-236.
98. Myers WD, Ng KT, Singer G, Smythe GA, Duncan MW. Dopamine and salsolinol levels in rat hypothalami and striatum after scheduleinduced self-injection (SISI) of ethanol and acetaldehyde. Brain Res. 1985;358:122-128.
99. Takayama S, Uyeno ET. Intravenous self-administration of ethanol and acetaldehyde by rats. Yakubutsu Seishin Kodo. 1985;5:329-334.
100. Bardo MT, Green TA, Crooks PA, Dwoskin LP. Nornicotine is selfadministered intravenously by rats. Psychopharmacology (Berl). 1999;146:290-296.
101. Clemens KJ, Caillé S, Stinus L, Cador M. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int J Neuropsychopharmacol. 2009;12:1355-1366.
102. Costello MR, Reynaga DD, Mojica CY, Zaveri N, Belluzzi JD, Leslie FM. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats [published online ahead of print 2014]. Neuropsychopharmacology. doi: 10.1038/npp.2014.31.
103. Caine SB, Collins GT, Thomsen M, Wright C, Lanier RK, Mello NK. Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine in male rodents. Exp Clin Psychopharmacol. 2014;22:9-22.
104. Hoffman AC, Evans SE. Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob Res. 2013;15:622-632.
105. Brioni JD, Kim DJ, O'Neill AB, Williams JE, Decker MW. Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res. 1994;643:1-9.
106. Goldberg SR, Risner ME, Stolerman IP, Reavill C, Garcha HS. Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology (Berl). 1989;97:295-302.
107. Takada K, Swedberg MD, Goldberg SR, Katz JL. Discriminative stimulus effects of intravenous l-nicotine and nicotine analogs or metabolites in squirrel monkeys. Psychopharmacology (Berl). 1989;99:208-212.
108. Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res. 1999;1:301-315.
109. Fattore L, Altea S, Fratta W. Sex differences in drug addiction: a review of animal and human studies. Womens Health (Lond Engl). 2008;4:51-65.
110. Donny EC, Caggiula AR, Rowell PP, et al. Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology (Berl). 2000;151:392-405.
111. Levin ED, Lawrence S, Petro A, Horton K, Seidler FJ, Slotkin TA. Increased nicotine self-administration following prenatal exposure in female rats. Pharmacol Biochem Behav. 2006;85:669-674.
112. Chaudhri N, Caggiula AR, Donny EC, et al. Sex differences in the contribution of nicotine and nonpharmacological stimuli to nicotine self-administration in rats. Psychopharmacology (Berl). 2005;180:258-266.
113. Grebenstein P, Burroughs D, Zhang Y, LeSage MG. Sex differences in nicotine self-administration in rats during progressive unit dose reduction: implications for nicotine regulation policy. Pharmacol Biochem Behav. 2013;114-115:70-81.
114. Rose JE, Behm FM, Westman EC, Bates JE. Mecamylamine acutely increases human intravenous nicotine self-administration. Pharmacol Biochem Behav. 2003;76:307-313.
115. Perkins KA, Jacobs L, Sanders M, Caggiula AR. Sex differences in the subjective and reinforcing effects of cigarette nicotine dose. Psychopharmacology (Berl). 2002;163:194-201.
116. Perkins KA, Gerlach D, Vender J, Grobe J, Meeker J, Hutchison S. Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob Res. 2001;3:141-150.
117. Perkins KA, Doyle T, Ciccocioppo M, Conklin C, Sayette M, Caggiula A. Sex differences in the influence of nicotine dose instructions on the reinforcing and self-reported rewarding effects of smoking. Psychopharmacology (Berl). 2006;184:600-607.